Gaithersburg-based genetic diagnostics company GeneDx reported a 49% year-over-year revenue increase in Q2 2025 to $102.7 million, driven largely by whole-exome and whole-genome testing which accounted for 84% of total revenues. The company revised its full-year revenue guidance upward to $400 million to $415 million, citing improved reimbursement rates and expanded test profitability. GeneDx plans to capitalize on new American Academy of Pediatrics guidelines to grow into the general pediatrics market, aiming to enhance awareness and payer coverage for genomic testing.